小罗伯特·肯尼迪 (Robert F. Kennedy Jr.) 被提名领导 HHS，Moderna 股价下跌

在当选总统唐纳德·特朗普提名小罗伯特·F·肯尼迪领导卫生与公众服务部后，Moderna Inc. 的股价下跌。

Shares of Moderna Inc (NASDAQ:MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Here’s what you need to know.

在当选总统唐纳德·特朗普提名小罗伯特·F·肯尼迪领导卫生与公众服务部后，Moderna Inc（纳斯达克股票代码：MRNA）的股价下跌。这是您需要了解的内容。

What To Know: Kennedy has been a vocal critic of vaccines and mainstream medical practices, raising concerns about potential reforms at federal health agencies, including the FDA and NIH. Speculation about reduced funding, department eliminations and restructuring at the NIH has created unease among employees and investors. FDA staff are reportedly considering resignations due to concerns about Kennedy's potential policies.

须知：肯尼迪一直直言不讳地批评疫苗和主流医疗实践，引起了人们对联邦卫生机构（包括 FDA 和 NIH）潜在改革的担忧。关于美国国立卫生研究院资金减少、部门撤销和重组的猜测引起了员工和投资者的不安。据报道，由于担心肯尼迪的潜在政策，FDA 工作人员正在考虑辞职。

Kennedy has proposed reducing the NIH's 27 divisions to 15 and replacing 600 employees, raising alarms about the future of federally funded research and its independence. Employees at the FDA and NIH are apprehensive about potential budget cuts and the politicization of research. For Moderna, this creates uncertainty about the future of vaccine development and approval processes.

肯尼迪提议将 NIH 的 27 个部门减少到 15 个，并更换 600 名员工，这对联邦资助的研究的未来及其独立性敲响了警钟。 FDA 和 NIH 的员工对潜在的预算削减和研究政治化感到担忧。对于 Moderna 来说，这给疫苗开发和审批流程的未来带来了不确定性。

Industry representatives, including the Pharmaceutical Research and Manufacturers of America, have expressed concerns about preserving innovation and maintaining the U.S.'s leadership in drug development. Despite the uncertainty, they indicated they may collaborate with the incoming administration to address healthcare challenges.

包括美国药物研究和制造商协会在内的行业代表对保留创新和维持美国在药物开发方面的领导地位表示担忧。尽管存在不确定性，但他们表示可能会与即将上任的政府合作应对医疗保健挑战。

Why It Matters: These developments have heightened investor fears about the pharmaceutical sector, particularly vaccine developers like Moderna, which rely on federal approval processes and public trust in immunization programs.

重要性：这些事态发展加剧了投资者对制药行业的担忧，尤其是像 Moderna 这样的疫苗开发商，这些公司依赖联邦审批程序和公众对免疫计划的信任。

The uncertainty surrounding federal health policies and their impact on vaccine programs is driving the sell-off in Moderna and other vaccine stocks. Shares are under pressure as investors weigh the potential for reduced government support and a more challenging regulatory environment.

联邦卫生政策的不确定性及其对疫苗计划的影响正在推动 Moderna 和其他疫苗股票的抛售。由于投资者权衡政府支持减少的可能性和更具挑战性的监管环境，股价面临压力。

MRNA Price Action: Moderna shares were down by 6.16% at $37.33 at the time of writing, according to Benzinga Pro.

MRNA 价格走势：据 Benzinga Pro 称，截至撰写本文时，Moderna 股价下跌 6.16%，至 37.33 美元。

Read Next:

阅读下一篇：